The South Korean government has launched a comprehensive policy to support pharmaceutical and bio ventures throughout their entire development cycle. This initiative is a follow-up to the ‘Everyone’s Startup Project’ announced at the National Startup Era Strategy Meeting on January 30, and is designed to strengthen the foundation for innovative drug creation. The global pharmaceutical market is rapidly expanding, and Korea has achieved significant milestones, including surpassing $10 billion in pharmaceutical exports and ranking among the top ten in biopharmaceutical exports. Despite these achievements, challenges such as funding gaps during clinical stages and commercialization delays have hindered sustained growth. The new policy aims to address these gaps and strategically foster companies with the potential to generate blockbuster drugs.
The policy impacts pharmaceutical and bio venture companies, research institutions, hospitals, and investors. Through the ‘Scale-Up TIPS Platform,’ promising ventures are jointly identified and supported by both government and private operators. Selected companies receive package support covering R&D, commercialization funding, and infrastructure access without additional evaluations. The government also prioritizes these ventures in technology guarantees and national drug development projects, minimizing funding gaps at critical clinical entry stages. Collaboration with global hubs like Boston CIC and Japan’s Shonan iPark is encouraged to facilitate international expansion.
Implementation began with a joint policy meeting held by the Ministry of SMEs and Startups and the Ministry of Health and Welfare on March 24, 2026, at the Korea Pharmaceutical and Bio Association in Seoul. The strategy centers on the ‘4UP’ approach: Scale-Up, Speed-Up, Level-Up, and Synergy-Up. New programs include AI-driven joint R&D, improved regulatory frameworks, and integrated monitoring systems. The government is also introducing virtual platforms to enhance infrastructure utilization and launching new projects to address early-stage support gaps. These measures are expected to create a seamless investment and development ecosystem, connecting research, commercialization, and global market entry.
Frequently asked questions include: What support do selected ventures receive? They are provided with integrated packages covering R&D, funding, and infrastructure, and are prioritized in subsequent government programs. How does the policy accelerate global collaboration? The government supports international partnerships and facilitates technology transfers through the ‘Global Open Innovation Activation Support Project.’ What is the expected impact? The policy aims to establish a virtuous cycle linking investment, research, commercialization, and global expansion, ultimately enhancing national health and industry competitiveness.
Metaqsol opinion: South Korea’s new policy provides a holistic framework for nurturing pharmaceutical and bio ventures, addressing critical gaps from R&D to commercialization and global expansion. The integrated approach, including the Scale-Up TIPS Platform and international collaboration initiatives, is grounded in proven industry needs and aims to create a seamless innovation pipeline. By prioritizing regulatory improvements and infrastructure utilization, the government is positioning Korea as a competitive player in the global pharmaceutical market. This strategy is expected to drive both economic growth and public health benefits.